Merck to buy ArQule, advancing leadership in oncology
Merck and ArQule announced Monday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion.